Swedish Orphan Biovitrum ABSWOBY 67 Current Ratio is 0.70 as of Mar. 2026, which is 27% below its 10-year median of 0.96. GuruFocus rates SWOBY with a GF Score™ of 67/100 and a GF Value™ of $17.17 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 998 Drug Manufacturers companies, Swedish Orphan Biovitrum AB ranks worse than 90.98% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Swedish Orphan Biovitrum AB's current ratio for the quarter that ended in Mar. 2026 was 0.70.
Swedish Orphan Biovitrum AB has a current ratio of 0.70. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Swedish Orphan Biovitrum AB has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Swedish Orphan Biovitrum AB's Current Ratio or its related term are showing as below:
SWOBY'
s Current Ratio Range Over the Past 10 Years
Min: 0.59 Med: 0.96 Max: 2
Current: 0.7
During the past 13 years, Swedish Orphan Biovitrum AB's highest Current Ratio was 2.00. The lowest was 0.59. And the median was 0.96.
SWOBY's Current Ratio is ranked worse than 90.98% of 998
companies
in the Drug Manufacturers industry
Industry Median: 2
vs SWOBY: 0.70
Swedish Orphan Biovitrum AB (OTCPK:SWOBY) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Swedish Orphan Biovitrum AB Current Ratio Related Terms
Swedish Orphan Biovitrum AB Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Swedish Orphan Biovitrum AB Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Current Ratio distribution charts can be found below:
* The bar in red indicates where Swedish Orphan Biovitrum AB's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Swedish Orphan Biovitrum AB (SWOBY) has a Current Ratio of 0.70 as of Mar. 2026. This is 27% below median its historical median of 0.96. Over the past decade, Swedish Orphan Biovitrum AB's Current Ratio has ranged from 0.59 to 2.00. According to the industry distribution chart, Swedish Orphan Biovitrum AB ranks #908 out of 998 companies in the Drug Manufacturers industry, placing it in the top 91%.
Is Swedish Orphan Biovitrum AB's Current Ratio too high?
Swedish Orphan Biovitrum AB's current Current Ratio of 0.70 is 27% below median its 10-year median of 0.96. Over the past 10 years, this metric has ranged from a low of 0.59 to a high of 2.00. The Drug Manufacturers industry median Current Ratio is 2.00. Swedish Orphan Biovitrum AB's value of 0.70 is 65% below this industry median. Based on the distribution chart, Swedish Orphan Biovitrum AB ranks #908 out of 998 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Swedish Orphan Biovitrum AB has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Swedish Orphan Biovitrum AB's Current Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Swedish Orphan Biovitrum AB ranks #908 out of 998 companies for Current Ratio. This places Swedish Orphan Biovitrum AB in the lower half of its industry. The industry median Current Ratio is 2.00. Swedish Orphan Biovitrum AB's value of 0.70 is 65% below this benchmark. Historically, Swedish Orphan Biovitrum AB's own Current Ratio has ranged from 0.59 to 2.00 over the past decade. While the company's 10-year median is 0.96 vs. the industry median of 2.00, Swedish Orphan Biovitrum AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 998 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Swedish Orphan Biovitrum AB's current Current Ratio of 0.70 is 65% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Swedish Orphan Biovitrum AB's current Current Ratio is 0.70, which is 27% below median its own 10-year median of 0.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Swedish Orphan Biovitrum AB stock overvalued right now?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB (SWOBY) is currently considered Significantly Overvalued. The stock's GF Value™ is $17.17, compared to a current price of $23.18 — trading 35% above its estimated fair value. The current Current Ratio is 0.70, which is 27% below median its 10-year median of 0.96 and 65% below the Drug Manufacturers industry median of 2.00. Swedish Orphan Biovitrum AB's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Swedish Orphan Biovitrum AB (SWOBY), the current Current Ratio is 0.70 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Swedish Orphan Biovitrum AB (SWOBY) Overvalued in 2026?
Based on GuruFocus' analysis, Swedish Orphan Biovitrum AB stock appears to be overvalued.
The current stock price of $23.18 is trading 35% above its estimated GF Value™ of $17.17.
GuruFocus considers Swedish Orphan Biovitrum AB to be Significantly Overvalued.
Key valuation signals for SWOBY:
Current Ratio: 0.70 (27% below median its 10-year median of 0.96)
GF Value™: $17.17 vs. price of $23.18 (35% above fair value)
Industry Position: 65% below the Drug Manufacturers median (#908 of 998)
No single metric tells the full story. See the SWOBY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) in 2006 on long-acting hemophilia factor replacement programs. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016, and Altuvoct in 2024. Sobi has been building its immunology pipeline (rare-disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drugs, complement drug Aspaveli) and a broader hematology pipeline (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).
67GF Score
Get the complete analysis for SWOBY
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SWOBY has been successfully added to your 
